These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 12913401)

  • 21. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
    Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
    Lev EI; Hasdai D; Scapa E; Tobar A; Assali A; Lahav J; Battler A; Badimon JJ; Kornowski R
    J Am Coll Cardiol; 2004 Mar; 43(6):966-71. PubMed ID: 15028351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
    Alexander JH; Harrington RA
    Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
    Schulman SP; Goldschmidt-Clermont PJ; Topol EJ; Califf RM; Navetta FI; Willerson JT; Chandra NC; Guerci AD; Ferguson JJ; Harrington RA; Lincoff AM; Yakubov SJ; Bray PF; Bahr RD; Wolfe CL; Yock PG; Anderson HV; Nygaard TW; Mason SJ; Effron MB; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt MM; Gerstenblith G
    Circulation; 1996 Nov; 94(9):2083-9. PubMed ID: 8901655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: the Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial.
    Gurbel PA; Cummings CC; Bell CR; Alford AB; Meister AF; Serebruany VL;
    Am Heart J; 2003 Feb; 145(2):239-47. PubMed ID: 12595840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypothermia-induced platelet aggregation: no effect of aprotinin (trasylol) but inhibition by eptifibatide (integrilin).
    Straub A; Azevedo R; Beierlein W; Wendel HP; Scheule AM; Ziemer G
    Thorac Cardiovasc Surg; 2005 Apr; 53(2):80-4. PubMed ID: 15786005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
    Dyke CM; Bhatia D; Lorenz TJ; Marso SP; Tardiff BE; Hogeboom C; Harrington RA
    Ann Thorac Surg; 2000 Sep; 70(3):866-71; discussion 871-2. PubMed ID: 11016325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI; Kereiakes DJ; Krueger LA; Mueller MN; Pieper K; Broderick TM; Schneider JF; Howard WL; Fox ML; Barnard MR; Frelinger AL; Michelson AD
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Peterson JG; Topol EJ; Roe MT; Sapp SK; Lincoff AM; Deckers JW; Blackstone EH; Harrington RA; Califf RM; Lauer MS
    Am J Cardiol; 2001 Mar; 87(5):532-6. PubMed ID: 11230834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
    Harrington RA
    Am Heart J; 1999 Oct; 138(4 Pt 2):276-86. PubMed ID: 10502233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
    Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
    Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
    Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
    Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes.
    Stringer KA
    Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.